Patents by Inventor Daofei LI

Daofei LI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Preparation of cyclosporin derivatives
    Patent number: 12673976
    Abstract: The invention provides a process for the preparation of cyclosporin derivatives.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: July 7, 2026
    Assignee: Farsight Medical Technology (Shanghai) Co., Ltd.
    Inventors: Fashu Ma, Ching-Pong Mak, Daofei Li, Xiao Yu
  • PREPARATION OF CYCLOSPORIN DERIVATIVES
    Publication number: 20230174583
    Abstract: The invention provides a process for the preparation of cyclosporin derivatives.
    Type: Application
    Filed: March 25, 2021
    Publication date: June 8, 2023
    Inventors: Fashu Ma, Ching-Pong Mak, Daofei Li, Xiao Yu
  • EGFR inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
    Patent number: 10561646
    Abstract: Provided is an EGFR inhibitor and a pharmaceutically acceptable salt and a polymorph thereof, and a use thereof. In particular, provided is a polymorph, a pharmaceutically acceptable salt or a prodrug of N-(2-(4-(dimethylamino)piperid-1-yl)-5-(5-fluoro-4-(1-methyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino)-4-methoxy phenyl) acrylamide. In addition, also provided is a pharmaceutical composition containing the inhibitor and a use thereof.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: February 18, 2020
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO. LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Jiong Lan, Taotao Jiang, Daofei Li, Xing Liu
  • EGFR INHIBITOR AND PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPH THEREOF, AND USE THEREOF
    Publication number: 20180319770
    Abstract: Provided is an EGFR inhibitor and a pharmaceutically acceptable salt and a polymorph thereof, and a use thereof. In particular, provided is a polymorph, a pharmaceutically acceptable salt or a prodrug of N-(2-(4-(dimethylamino)piperid-1-yl)-5-(5-fluoro-4-(1-methyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino)-4-methoxy phenyl) acrylamide. In addition, also provided is a pharmaceutical composition containing the inhibitor and a use thereof.
    Type: Application
    Filed: July 25, 2016
    Publication date: November 8, 2018
    Inventors: Jiong LAN, Taotao JIANG, Daofei LI, Xing LIU